Expression of peripheral blood NKT and NK cells in postoperative colorectal cancer patients before and after chemotherapy / 中国现代医生

Objective To observe the changes of peripheral blood lymphocyte subsets in patients with postoperative colorectal cancer before and after chemotherapy, and to evaluate the changes of immune function status. Methods 74 patients with stage Ⅱ-Ⅲ colorectal cancer after radical resection admitted in Zhejiang Cancer Hospital from January to December 2016 were enrolled. 25 non-malignant patients in the same period in our hospital were selected as the control group. Flow cytometry was used to analyze the proportion of peripheral blood lymphocyte subsets at one day before the first, sixth and eighth cycles of adjuvant chemotherapy. Results There were no differences in CD3+ (P =0.1532), CD3+CD4+ (P=0.1107), CD3+CD8+ (P=0.2576) T cells in the peripheral blood between patients with colorectal cancer after radical operation and control group (P>0.05). While CD3+CD56+NKT cells (P=0.0210) and CD3-CD56+NK cells (P=0.0045) in the patients with colorectal cancer after radical operation were significantly higher than those of the control group (P <0.05). There was no significant change in the proportion of NK and NKT cells before 6 cycles of postoperative adjuvant chemotherapy (P>0.05). There was no significant change in the proportion of NKT cells before 8 cycles (P>0.05), and the proportion of NK cells only decreased slightly (19.10±4.63 vs 20.31±4.66, P=0.046). Conclusion The proportion of NK and NKT cells in patients with colorectal cancer after radical resection was significantly higher than that in healthy people, and the expression rate remains stable after adjuvant chemotherapy.

S-1 in advanced gastric cancer treatment / 国际肿瘤学杂志

S-1 is an upgraded product of tegafur and UFT. Compared with 5-FU, it has stronger anticancer activity, and relative rare gastrointestinal adverse reaction. Many clinical studies have demonstrated S-1 has very good efficacy and safety in patients with advanced gastric cancer. The efficacy of single S-1 has been approved better than other available anti-cancer drugs in the treatment of gastric cancer, and similar to combination regimens such as cisplatin plus fluorouracil.